4.390CHF-1.70%Mkt Cap: 1.12B CHFP/E: —Last update: 2026-06-01
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.12B CHF
Enterprise Value2.38B CHF
Revenue (TTM)220.58M CHF
Gross Profit199.67M CHF
Net Income (TTM)-111.70M CHF
Revenue/Share1.027 CHF
Last Price4.390 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees424
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0363463438
Valuation
P/E (Trailing)—
P/E (Forward)-34.56
PEG—
EV/EBITDA-24.02
EV/Revenue10.78
P/S5.16
P/B-0.98
EPS (TTM)-0.96
EPS (Forward)-0.13
52W Range
1.48886% of range4.870
52W High4.870 CHF
52W Low1.488 CHF
Profitability
Gross Margin90.52%
Oper. Margin-108.00%
EBITDA Margin-44.90%
Profit Margin-50.64%
ROE9.82%
ROA-23.98%
Growth
Revenue Growth-19.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-153.23M CHF
CapEx (TTM)13.82M CHF
FCF Margin-59.62%
FCF Yield-11.75%
Net Debt1.18B CHF
Net Debt/EBITDA-11.90
Balance Sheet
Debt/Equity-1.11
Current Ratio1.39
Quick Ratio0.81
Book Value/Sh-4.5350 CHF
Cash/Share0.3530 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 16, 2017
Pay DateOct 13, 2020
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)4.500 CHF
Target Range4.000 CHF – 5.000 CHF
# Analysts3
Ownership
Shares Out.255.04M
Float155.85M
Insiders30.52%
Institutions27.21%
Technical
SMA 503.751 (+17.0%)
SMA 2003.678 (+19.4%)
Beta1.66
S&P 52W Chg27.70%
Avg Vol (30d)1.92M
Avg Vol (10d)2.05M
Technical Indicators
RSI (14)59.8
MACD0.2015
MACD Signal0.1638
MACD Hist.+0.0378
BB Upper4.758 CHF
BB Middle4.092 CHF
BB Lower3.425 CHF
BB Width32.57%
ATR (14)0.2960 CHF
Vol Ratio (20d)1.33x